{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Adenoid+Cystic&page=2", "query": { "condition": "Carcinoma, Adenoid Cystic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Adenoid+Cystic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T10:12:56.778Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07667400", "title": "Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Paranasal Sinus Neoplasms", "Nasopharyngeal Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Hypopharyngeal Cancer", "Carcinoma of Larynx", "Oral Squamous Cell Carcinoma", "Salivary Gland Cancer", "Adenoid Cystic Carcinoma", "Prostate Cancer", "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "SX-682", "type": "DRUG" }, { "name": "DTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 120, "start_date": "2026-07-28", "completion_date": "2037-10-01", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07667400" }, { "nct_id": "NCT00003565", "title": "Docetaxel in Treating Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Head and Neck Cancer", "Lung Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "1998-09", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 72, "location_summary": "Anniston, Alabama • La Jolla, California • San Diego, California + 52 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003565" }, { "nct_id": "NCT03990571", "title": "Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Adenoid Cystic Carcinoma", "Progressive Disease", "Recurrent Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-07-22", "completion_date": "2023-03-20", "has_results": true, "last_update_posted_date": "2024-10-18", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03990571" }, { "nct_id": "NCT00006799", "title": "Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anorexia", "Cachexia", "Head and Neck Cancer", "Quality of Life" ], "interventions": [ { "name": "megestrol acetate", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 13, "start_date": "2000-10-01", "completion_date": "2002-09-06", "has_results": false, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006799" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" }, { "nct_id": "NCT01156142", "title": "Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer", "Mucositis", "Oral Complications of Radiation Therapy", "Pain" ], "interventions": [ { "name": "doxepin hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2010-12", "completion_date": "2015-03-02", "has_results": true, "last_update_posted_date": "2017-08-09", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 120, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01156142" }, { "nct_id": "NCT00089362", "title": "Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Gastric Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Melanoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Ovarian Epithelial Cancer", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Colon Cancer", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Gastric Cancer", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Melanoma", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Melanoma", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Ovarian Epithelial Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "alvespimycin hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089362" }, { "nct_id": "NCT04140526", "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Advanced Solid Tumor", "Metastatic Melanoma", "Metastatic Head and Neck Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Colorectal Cancer", "Sarcomas", "Metastatic Prostate Cancer", "Ovarian Cancer", "Small Cell Lung Cancer", "Metastatic Breast Cancer", "Pancreas Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Cervical Cancer", "Adenoid Cystic Carcinoma", "Salivary Gland Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "ONC-392", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoC4, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 733, "start_date": "2020-09-16", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 33, "location_summary": "Springdale, Arkansas • Davis, California • Downey, California + 27 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Davis", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04140526" }, { "nct_id": "NCT00002533", "title": "Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Head and Neck Cancer", "Infection", "Oral Complications" ], "interventions": [ { "name": "fluconazole", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "21 Years to 120 Years" }, "enrollment_count": null, "start_date": "1993-02", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002533" }, { "nct_id": "NCT00023959", "title": "Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "hydroxyurea", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2001-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-07-24T10:12:56.778Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023959" } ] }